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Hashimoto’s thyroiditis (HT) may occur associated with celiac disease (CD). Regulatory B cells (Breg) subsets have been shown to
play a signiﬁcant role in autoimmune processes. Therefore, we have characterized their distribution in the peripheral blood
obtained from 10 patients with isolated HT, 10 patients with HT+CD, 9 patients with isolated CD, and 9 healthy donors (HD).
Th17 cells were signiﬁcantly increased in patients with HT and in patients bearing both HT and CD, while patients with
isolated CD exhibited a lower percentage of Th17, as compared with healthy donors. CD24hiCD38hi Breg cells were signiﬁcantly
higher in patients with HT+CD and in patients with isolated CD as compared to both HD patients and patients with isolated
HT (p = 0 0010). On the contrary, Breg memory phenotypes (CD24hiCD38− and CD24hiCD27+) signiﬁcantly decreased in
patients with HT+CD as compared with the isolated disorders. Following CpG oligodeoxynucleotide stimulation, IL-10+
CD24hiCD38hi Breg cells were similar in all groups of patients, despite these cells would have been higher in CD patients. In
conclusion, celiac disease, isolated and even more when associated with HT, determines a peculiar behavior of Breg cells
which are increased in number but possibly functionally defective. Furthermore, the association CD+HT was characterized by
a reduction of Breg memory subsets as compared with the isolated disorders. The behavior of Th17 subset in patients with
celiac disease associated with HT might have been sensitive to the eﬀect of long-lasting GFD, and it is essentially determined
by the presence of thyroid autoimmunity.
1. Introduction
Recent evidence has stressed that regulatory B (Breg) cells
represent novel actors in maintaining the immune tolerance
along with Th17 and regulatory T (Treg) cells [1, 2]. Breg
cells, therefore, gained interest when studying autoimmune
disorders [3]. The more frequent autoimmune disorder is
autoimmune thyroid disease which may occur with other
endocrine and nonendocrine autoimmune disorders [4–8].
One of the most relevant is represented by celiac disease
(CD) which has been described in a signiﬁcant number of
patients with Hashimoto’s thyroiditis (HT) [9, 10] as well
as with other common autoimmune endocrine disorders
[5, 10, 11]. The role of cellular immune response in the
pathogenesis of these autoimmune disorders has been par-
tially clariﬁed [6–8]. As a matter of fact, in HT, a prevailing
CD4+ Th1 polarization has been at ﬁrst described [6, 7],
but recently, it has been also described an involvement of
Th17 cells in its pathogenesis [12, 13]. Th17 polarization is
a characteristic of inﬂammatory phase of auto aggressive dis-
orders and may precede Th1 phase of HT [12]. Cellular
immune response is also relevant in CD pathogenesis: circu-
lating Th17 cell levels were increased in adult patients, and
they seemed to normalize upon appropriate gluten-free diet
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(GFD) [14]. Also, Treg cells, which maintain the peripheral
tolerance [3], were increased in active CD and returned at
normal levels after GFD [15]. Recently, it has been described
that the CD19+ Breg cells may play a relevant role in damp-
ening the T lymphocyte eﬀector pathways Th1 and Th17
and enhancing Treg cells through the modulation of FoxP3
gene [16]. Breg cells’ regulatory mechanism is far from
being elucidated, despite the fact that production of IL-10
by some Breg subsets seems to be key in this network
[17]. In fact, some diﬀerent Breg subsets have been
described, the main phenotypes being CD24hiCD38hi Breg
cells and memory Breg cells expressing CD27+on the cell
surface [18, 19]. There are only few published studies on
the characterization of Breg cells in patients with Hashimo-
to’s thyroiditis either isolated [20, 21] or associated with
other autoimmune disorders [22]. How the behavior of cir-
culating Breg cells in celiac disease would be modiﬁed by the
simultaneous presence of HT is not known and represents
the aim of our study.
2. Patients and Methods
2.1. Patients. A total of 38 patients (34 women and 4 men;
median age 45 years, IQ1-IQ3=35–45 years) were enrolled:
9 were healthy donors (HD), 10 patients were aﬀected by
isolated HT, 10 patients by CD and HT (CD+HT), and 9
by isolated CD. Their anthropometric and biochemical char-
acteristics are shown in Table 1. The diagnoses have been
established according to the speciﬁc guidelines or consensus
[23, 24]. In particular, CD patients have been diagnosed
before the age of 12. Celiac disease had been diagnosed by
the presence of positive antiendomysial (EMA) and anti-
transglutaminase (tTG) antibodies and conﬁrmed by endos-
copy. Their histological damage has been classiﬁed as Marsh
IIIa (n = 13) and Marsh IIIb (n = 6) [24]. They were slightly
younger than the sample patients without celiac disease,
and their levels of cholesterol and triglycerides were also
slightly lower (Table 1). All CD patients were in gluten-free
diet since almost 12 months, as demonstrated by the disap-
pearance of clinical symptoms and the absence of previously
positive antiendomysial (EMA) and antitransglutaminase
(tTG) antibodies [25]. Patients with Hashimoto’s thyroiditis
had been diagnosed by the conﬁrmed presence of antithyro-
peroxidase antibodies, the characteristic ultrasonographic
pattern, and the presence of hypothyroidism [23]. All HT
patients were subclinically hypothyroid and were similarly
treated by titrating thyroxine dose individually, as previously
described [9, 26]. At the time of sampling, HT patients were
all euthyroid. In the whole sample, no patients had evidence
of chronic disorders (diabetes, chronic obstructive pulmo-
nary disease, obesity, renal failure, and cancer) nor infections
and/or inﬂammatory disorders in the last 6 months and were
neither pregnant nor nursing. Patients treated with drugs
interfering with the immune response (steroids, immuno-
suppressant, and immune-modulatory and nonsteroidal
anti-inﬂammatory drugs) were not enrolled. The study has
been approved by the local Ethical Committee (Santa Maria
Goretti Hospital, Latina, Italy) according to the local ethical
rules and to the guidelines in the Declaration of Helsinki.
Written informed consent from all patients was obtained
before the beginning of the study.
2.2. Methods. PBMCs were collected from all enrolled sub-
jects as already reported [22]. Fresh PBMCs were stained
with speciﬁc antibodies. The characterized phenotype of
Th17 was CD4+ IL17A+, and the results are expressed as
percentages of total CD4+ T lymphocytes.
The results for B cell subset analysis are expressed as
percentages of total CD19+ B lymphocytes. The following
phenotypes were characterized:
(i) Total B cells =CD19+
(ii) Breg cells =CD19+CD24hiCD38hi
(iii) “Primary” Breg memory cells =CD19+CD24hi-
CD38neg
(iv) Breg memory cells =CD19+CD24hiCD27+
For both T and B cells, cells were stimulated with
PMA, Ionomycin, Brefeldin A, and Monensin (PIB) (cell
stimulation cocktail plus protein transport inhibitor, Aﬀy-
metrix eBioscience, San Diego, CA, USA) in the last 5
hours.
T cells were surface-stained with anti-CD4 FITC anti-
body, ﬁxed, permeabilized, and stained intracellularly with
anti-IL-17A PE antibody (Aﬀymetrix eBioscience, San Diego,
CA, USA).
Table 1: Anthropometric and biochemical characteristics of patients.
HD HT HT+CD CD p
Subjects (no.) 9 10 10 9 N/A
Sex (women/male) 8W/1M 8W/2M 9W/1M 9W N/A
Age (years) median (IQ1-IQ3) 49 (39–54) 47 (42–57) 39 (22–49) 37 (29–44) ns
Weight (Kg) median (IQ1-IQ3) 67 (60–72) 67 (60–79) 54 (51–58) 60 (56–72) 0.0448
Total cholesterol (mg/dL) median (IQ1-IQ3) 190 (173–210) 201 (186–226) 177 (147–201) 174 (150–198) ns
Triglycerides (mg/dL) median (IQ1-IQ3) 101 (90–126) 120 (100–136) 82 (61–110) 77 (57–109) 0.0431
TSH at ﬁrst examination (mU/L) median (IQ1-IQ3) 1.20 (0.90–2.1) 12.80 (10.96–17.7) 14.50 (12.95–16.52) 1.48 (0.99–2.13) N/A
TSH under L-T4 therapy (mU/L) median (IQ1-IQ3) N/A 1.22 (0.96–1.72) 1.10 (0.95–1.52) N/A ns
HT =Hashimoto’s thyroiditis; CD = celiac disease.
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B cells were surface-stained with anti-CD19 FITC,
anti-CD24 APC-eFluor 780, anti-CD38 APC, and anti-
CD27 PerCPcy5.5 antibodies, ﬁxed, permeabilized, and
intracellular-stained with anti-IL-10 PE antibody (Aﬀyme-
trix eBioscience, San Diego, CA, USA).
To evaluate IL-10 production by Breg cells, PBMCs were
incubated with 0.1μM CpG-B ODN2006 (InvivoGen, San
Diego, CA, USA) for 72 hours at 37°C.
CpG motifs contain a cytosine (C) followed by a guanine
(G) triphosphate deoxynucleotide with a phosphodiester (p)
link. CpG oligodeoxynucleotides are short single-stranded
synthetic DNA immunostimulants that have been consid-
ered pathogen-associated molecular pattern (PAMP) mole-
cules. They are recognized by the pattern recognition
receptor (PRR) Toll-Like Receptor 9 (TLR9) [22]. As a nega-
tive control, PBMCs were also incubated with non-CpG
ODN 2006 Control (ODN 2137, InvivoGen, San Diego,
CA, USA) in the same conditions. Moreover, the intracellular
staining was performed with an appropriate isotype control
Abs for gate setting (Aﬀymetrix eBioscience, San Diego,
CA, USA).
Data from these phenotypes are expressed as percentages
of IL-10-positive cells referred to the corresponding B
lymphocyte subsets.
(i) Total B cells IL10+=CD19+ IL10+
(ii) IL10+ Breg cells =CD19+CD24hiCD38hi IL10+
(iii) “Primary” IL10+ Breg memory cells =CD19+-
CD24hiCD38neg IL10+
(iv) IL10+ Breg memory cells =CD19+CD24hiCD27+
IL10+
Cells were acquired on a FACS ARIA II ﬂow cytometer
(Becton Dickinson, San Jose, CA, USA). At least 10,000
events were acquired on CD4+ or CD19+ gate. FACS Diva
software (v6.11, Becton Dickinson) was used for analysis.
2.3. Statistical Analysis. Results are expressed as median
value. The diﬀerence among more than two groups was cal-
culated using nonparametric Kruskal-Wallis test and Dunn
posttest to compare all pairs of data.
INSTAT GraphPad Prism 5.0 software for Windows
(GraphPad, La Jolla, Ca. USA) was used for the statistical
analysis.
3. Results
3.1. Th17 Lymphocytes. The median percentage of Th17 cells
was diﬀerent in each group of patients (Kruskal-Wallis test:
p = 0 0011). As expected, Th17 cells were signiﬁcantly
increased in patients with isolated HT, as compared with
healthy donors. In patients bearing both HT and CD, the
diﬀerence with healthy donors was even greater, while
patients with isolated CD exhibited a lower percentage of
Th17 (Figure 1).
3.2. B Lymphocyte Subsets. Total CD19+ B lymphocytes were
similar in all groups of patients (p = 0 3032, data not shown).
3.2.1. CD24hiCD38hi Bregs. The analysis of this subset
revealed signiﬁcant diﬀerences (Kruskal-Wallis test: p =
0 001) (Figure 2). The median percentage of CD24hiCD38hi
Breg cells was 2.0% both in HD patients and in patients with
isolated HT. Higher percentages were instead recorded in
patients with isolated CD and in those with CD+HT which
were, however, similar each other (p = ns). In particular,
patients bearing both HT and CD showed signiﬁcantly
higher Breg subset than HD and HT patients (Figure 2).
3.2.2. Memory Breg Subsets. The median percentage of the
“primary” memory Breg cells (CD19+CD24hiCD38negcells)
was signiﬁcantly decreased in CD+HT patients, being statis-
tically diﬀerent from isolated HT and CD (Kruskal-Wallis
test: p = 0 0065) (Figure 3(a)).
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Figure 1: Th17. Percentage of Th17 cells (CD4 + IL17A+) in
healthy donors (HD), in patients with Hashimoto thyroiditis
(HT), in patients with Hashimoto thyroiditis plus celiac disease
(HT+CD), and in patients with celiac disease (CD). Box plots
indicate median, interquartile range (box), and minimum and
maximum values (whiskers). Nonparametric Kruskal-Wallis test
p = 0 0011. Dunn posttest: HD vs HT p < 0 05; HD vs HT+CD
p < 0 01; HT +CD vs CD p < 0 05.
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Figure 2: Nonstimulated Breg cells. Percentage of Breg cells
(CD24hi CD38hi) in healthy donors (HD), in patients with isolated
Hashimoto thyroiditis (HT), in patients with Hashimoto
thyroiditis plus celiac disease (HT+CD), and in patients with
celiac disease (CD). Box plots indicate median, interquartile range
(box), and minimum and maximum values (whiskers).
Nonparametric Kruskal-Wallis test p = 0 0010. Dunn posttest:
HD vs HT+CD p < 0 05; HT vs HT+CD p < 0 01; HT vs CD
p < 0 05.
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These ﬁndings have been mirrored by the ones obtained
when CD19+CD24hiCD27+ memory cells were measured.
Again, the percentage of these memory cells was lower in
patients with CD+HT than in patients bearing the two dis-
eases in isolated form (Kruskal-Wallis test: p = 0 0122)
(Figure 3(b)). This may imply that memory CD24hiCD38neg
and CD27+ B cells overlapped; in fact, we found that more
than 2/3 of CD19+CD27+ cells also include the phenotype
CD24hiCD38neg.
3.3. CpG Stimulation
3.3.1. CD24hiCD38hi Bregs. Following CpG stimulation, total
CD19+cells were diﬀerent among groups (Kruskal-Wallis
p = 0 0098), and in particular, patients with isolated CD
showed a signiﬁcant reduction of this phenotype as com-
pared to the one observed in HD patients and in patients
with HT+CD (1.6% vs 3.9% or 4.2%; both p < 0 05). Even
the proportions of CD24hiCD38hi Bregs were signiﬁcantly
diﬀerent among groups (p = 0 0159), the Breg fraction
being higher in patients with isolated CD (Figure 4). On
the contrary, when these CpG-stimulated lymphocytes
were stratiﬁed by their IL-10 production, no diﬀerences
were observed among groups (p = ns, data not shown).
3.3.2. Memory Breg Subsets. Small but signiﬁcant diﬀerences
were observed in memory CD19+CD24hiCD38neg cells fol-
lowing CpG stimulation (p = 0 0362). A decreased percent-
age of this subset was observed in CD+HT patients as
compared to the one observed in isolated HT (p < 0 05).
The behavior of this memory subset seems to mirror the
one in nonstimulated Breg. On the contrary, the percentage
of CD19+CD27+ cells was similar in all subgroups (p = ns).
Furthermore, IL-10 expression after CpG stimulation was
similar in both subgroups of memory Breg cells (data not
shown).
4. Discussion and Conclusion
Celiac disease and Hashimoto’s thyroiditis often occur
associated [4, 5, 9, 10] and share some immunologic similar-
ities [9]. It appears to be useful, therefore, to look for
immunologic variations when the two disorders coexist
in the same patients.
These data show that, in patients with CD, the percentage
of TH17 cells was low and similar to the one observed in
healthy donors, as expected in gluten-free diet patients in
whom the inﬂammatory damage is no longer active [14]. In
contrast, there was a signiﬁcant increase of TH17 cells in
patients with HT [12] even when it coexists with CD. The
percentage of nonstimulated CD24hiCD38hi Breg cells was
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Figure 3: Nonstimulated Breg memory cells. (a) Percentage of Breg memory cells (CD24hi CD38−) in healthy donors (HD), in patients with
isolated Hashimoto thyroiditis (HT), in patients with Hashimoto thyroiditis plus celiac disease (HT+CD), and in patients with celiac disease
(CD). Box plots indicate median, interquartile range (box), and minimum and maximum values (whiskers). Nonparametric Kruskal-Wallis
test p = 0 0065. Dunn posttest: HT vs HT+CD p < 0 05 and HT+CD vs CD p < 0 05. (b) Percentage of Breg memory cells (CD24hi CD27+) in
healthy donors (HD), in patients with isolated Hashimoto thyroiditis (HT), in patients with Hashimoto thyroiditis plus celiac disease (HT
+CD), and in patients with celiac disease (CD). Box plots indicate median, interquartile range (box), and minimum and maximum values
(whiskers). Nonparametric Kruskal-Wallis test p = 0 0122. Dunn posttest: HT vs HT+CD p < 0 05 and HT+CD vs CD p < 0 05.
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Figure 4: Stimulated IL-10+ Breg cells. Percentage of IL10+ Breg
cells (CD24hi CD38hi IL10+) after CpG stimulation in healthy
donors (HD), in patients with isolated Hashimoto thyroiditis
(HT), in patients with Hashimoto thyroiditis plus celiac disease
(HT+CD), and in patients with celiac disease (CD). Box plots
indicate median, interquartile range (box), and minimum and
maximum values (whiskers). Nonparametric Kruskal-Wallis test
p = 0 0159. Dunn posttest: HT vs CD p < 0 05. Analysis of IL-
10-producing cells was performed on the previously shown B
lymphocyte subsets (CD24hi CD38hi cells).
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increased in patients with CD even when associated with HT
but not in patients with isolated HT, thus indicating that CD
may enhance this regulatory response, as described for
chronic intestinal inﬂammatory conditions by Mizoguchi
et al. [27]. We also observed a small but signiﬁcant decrease
percentage of both primary CD24hiCD38neg Breg cells and
memory Breg cells (CD24hiCD27+) in patients with CD
+HT. In fact, when CD and HT concurred, memory Breg
cells were signiﬁcantly lower than in patients with both iso-
lated disorders, indicating that the association of these auto-
immune disorders exerted an opposite eﬀect on Breg and
Breg memory cells. This is in keeping with our previous
results [22], since we described that Breg cells are quantita-
tively increased in patients with HT and further autoimmune
disorders; however, in this study, we have shown that this
eﬀect was seen even in patients with isolated CD, showing a
prevailing role of this disease over HT on the expression of
CD24hiCD38hi Breg cells. This was not the case for Breg
memory cells, where the copresence of HT and CD resulted
in a negative synergistic eﬀect, leading to a clearly reduced
CD19+CD24hiCD38neg subset. Again, these results are in
keeping with our previous study with multiple auto aggres-
sive disorders associated with HT [22].
It has been reported that naïve and memory B cells are
distinguished by the production of diﬀerent pro- and anti-
inﬂammatory cytokines: naïve B cells mainly produce anti-
inﬂammatory cytokines, whereas memory B cells are the
main responsible for proinﬂammatory cytokine production
[28–30]. IL-10 production has been considered as a proof
of functionality of Breg cells [1, 2], being enhanced in vitro
by CpG and/or other stimuli. In a previous study from
Kristensen et al. [20], CpG stimulus increased Breg cell
subsets in HT patients, but the eﬀect was similar to that
observed in healthy donors. On the contrary, in our previ-
ous study, CpG stimulus increased IL10+ Bregs in HT
patients signiﬁcantly more than in healthy donor, but no
further diﬀerences were observed in patients with multiple
autoimmune disorders [22]. Similar results were obtained
in our present study in patients with HT and celiac disease
that did not show any change in the percentage of IL10+
Bregs despite the increased number of these cells. Notice-
ably, a recent paper from Yu et al. [21] described the lack
of CD24hiCD38hi IL10+cells associated with a reduced reg-
ulatory activity and inability to suppress inﬂammatory
cytokines in patients with HT. However, this ﬁnding, even
in our patients, cannot rule out the regulatory eﬀects of
Bregs through other pathways (i.e., TGFbeta) as previously
described [28]. A further issue to be kept on mind about
our study group, as well as in general, is the phase of
autoimmune disorders in which the patients have been
studied. In fact, our patients were all in GFD since at least
12 months which usually reduces the inﬂammatory phase
at the level of duodenal mucosa [14, 17]. Both CD and
HT are considered autoimmune disorders with an initial
Th17 polarization [12, 31, 32] which activity may be coun-
teracted by increased IL10+Breg cells, leading to proin-
ﬂammatory cytokine suppression [33]. Our patients were
clearly outside the inﬂammatory phase of CD, and the
patients with HT were euthyroid because they are treated
with levothyroxine, whose anti-inﬂammatory eﬀect has
been recently described [34]. Therefore, our patients are
supposed to be in a phase in which inﬂammation is not
the prevailing characteristic. The reason why the memory
subsets are furthermore reduced in patients with HT
+CD, as compared to what is found in the isolated forms
of diseases, deserves further studies.
In conclusion, in patients with celiac disease, isolated
and even associated with HT, there emerges a peculiar
behavior of Breg cells which are increased in number but
possibly functionally defective. Furthermore, the associa-
tion CD+HT was signiﬁcantly associated with a reduction
of Breg memory subsets as compared with the isolated disor-
ders. Finally, the behavior of Th17 subset in patients with
celiac disease associated with HT might have been sensitive
to the eﬀect of long-lasting GFD, and it is essentially deter-
mined by the presence of thyroid autoimmunity.
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